Calamos Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$68.4M Sell
139,230
-30,670
-18% -$16.6M 0.24% 90
2025
Q4
$98.4M Buy
169,900
+22,200
+15% +$12.6M 0.37% 48
2025
Q3
$71.6M Buy
147,700
+27,510
+23% +$12.8M 0.26% 79
2025
Q2
$48.7M Sell
120,190
-22,500
-16% -$9.41M 0.19% 117
2025
Q1
$71M Sell
142,690
-3,110
-2% -$1.68M 0.31% 66
2024
Q4
$75.8M Buy
145,800
+3,458
+2% +$1.9M 0.32% 59
2024
Q3
$88M Buy
142,342
+1,672
+1% +$990K 0.38% 47
2024
Q2
$77.8M Sell
140,670
-3,011
-2% -$1.72M 0.35% 52
2024
Q1
$83.5M Buy
143,681
+58
+0% +$32.5K 0.4% 49
2023
Q4
$76.2M Sell
143,623
-23,327
-14% -$11.3M 0.37% 55
2023
Q3
$84.5M Buy
166,950
+7,011
+4% +$3.74M 0.44% 39
2023
Q2
$83.4M Buy
159,939
+12,622
+9% +$6.81M 0.41% 45
2023
Q1
$84.9M Sell
147,317
-11,999
-8% -$6.76M 0.41% 46
2022
Q4
$87.7M Sell
159,316
-37,886
-19% -$20.1M 0.41% 44
2022
Q3
$100M Buy
197,202
+10,783
+6% +$6.03M 0.46% 30
2022
Q2
$101M Buy
186,419
+9,333
+5% +$5.14M 0.44% 33
2022
Q1
$105M Buy
177,086
+4,401
+3% +$2.53M 0.39% 38
2021
Q4
$115M Buy
172,685
+40,532
+31% +$25.3M 0.43% 33
2021
Q3
$75.5M Buy
132,153
+35,890
+37% +$19.7M 0.33% 69
2021
Q2
$48.6M Sell
96,263
-12,858
-12% -$6.07M 0.22% 115
2021
Q1
$49.8M Sell
109,121
-34,820
-24% -$16.6M 0.27% 83
2020
Q4
$67M Buy
143,941
+6,691
+5% +$3.14M 0.39% 53
2020
Q3
$60.6M Buy
137,250
+43,231
+46% +$17.9M 0.39% 53
2020
Q2
$34.1M Sell
94,019
-2,962
-3% -$993K 0.24% 117
2020
Q1
$27.5M Sell
96,981
-42,086
-30% -$13.3M 0.22% 137
2019
Q4
$45.2M Sell
139,067
-1,133
-0.8% -$344K 0.22% 128
2019
Q3
$40.8M Buy
140,200
+5,131
+4% +$1.47M 0.22% 131
2019
Q2
$39.7M Buy
135,069
+2,618
+2% +$721K 0.22% 132
2019
Q1
$36.3M Sell
132,451
-11
-0% -$2.74K 0.23% 145
2018
Q4
$29.6M Buy
132,462
+6,769
+5% +$1.59M 0.2% 152
2018
Q3
$30.7M Sell
125,693
-18,165
-13% -$4.18M 0.17% 162
2018
Q2
$29.8M Sell
143,858
-2,061
-1% -$437K 0.18% 151
2018
Q1
$30.1M Buy
145,919
+2,643
+2% +$555K 0.2% 143
2017
Q4
$27.2M Sell
143,276
-3,988
-3% -$764K 0.14% 162
2017
Q3
$27.9M Buy
147,264
+2,267
+2% +$411K 0.22% 144
2017
Q2
$25.3M Sell
144,997
-21,685
-13% -$3.64M 0.19% 162
2017
Q1
$25.6M Buy
166,682
+83,598
+101% +$12.8M 0.2% 153
2016
Q4
$11.7M Sell
83,084
-1,158
-1% -$171K 0.09% 243
2016
Q3
$13.4M Buy
84,242
+236
+0.3% +$36.4K 0.1% 240
2016
Q2
$12.4M Sell
84,006
-25,369
-23% -$3.74M 0.09% 247
2016
Q1
$15.5M Buy
109,375
+31,200
+40% +$4.18M 0.1% 217
2015
Q4
$11.1M Buy
78,175
+1,218
+2% +$162K 0.07% 260
2015
Q3
$9.41M Buy
76,957
+27
+0% +$3.52K 0.06% 270
2015
Q2
$9.98M Sell
76,930
-4,340
-5% -$566K 0.06% 263
2015
Q1
$10.9M Buy
81,270
+48
+0.1% +$6.19K 0.07% 255
2014
Q4
$10.2M Buy
81,222
+422
+0.5% +$51.3K 0.07% 265
2014
Q3
$9.83M Hold
80,800
0.07% 259
2014
Q2
$9.53M Buy
80,800
+5,800
+8% +$683K 0.06% 254
2014
Q1
$9.02M Hold
75,000
0.06% 254
2013
Q4
$8.35M Hold
75,000
0.05% 259
2013
Q3
$6.91M Buy
75,000
+30,000
+67% +$2.71M 0.04% 270
2013
Q2
$3.81M Buy
+45,000
New +$3.75M 0.02% 317

Other funds holding TMO

Calamos Advisors's TMO Position: Q1 2026 in Review

Calamos Advisors reduced its Thermo Fisher Scientific (TMO) stake by 18% in Q1 2026, selling an estimated $16.6M and leaving 139,230 shares worth $68.4M. The position accounts for 0.24% of the portfolio, ranked #90.

Calamos Advisors first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $115M in Q4 2021. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Calamos Advisors held 139,230 shares of Thermo Fisher Scientific worth $68.4M as of Q1 2026.
  • Calamos Advisors sold 30,670 Thermo Fisher Scientific shares in Q1 2026, an estimated $16.6M.
  • Thermo Fisher Scientific made up 0.24% of Calamos Advisors's portfolio in Q1 2026, its #90 holding.
  • Calamos Advisors first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's Thermo Fisher Scientific position peaked at $115M in Q4 2021.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.